1. Pink Sheet
  2. >>Market Access

Orchard To Work On Reversing English Funding Refusal For Libmeldy Gene Therapy

Reimbursement Discussions Are Also Ongoing In Other Major European Markets

 
• By Neena Brizmohun

Health technology assessment body NICE has welcomed further discussion between Orchard Therapeutics and the National Health Service to resolve its concerns over the company’s one-time gene therapy for the neurodegenerative disorder, metachromatic leukodystrophy, in children.

Close up.employees discuss financial data. photo with copy space
Orchard is gearing up for further discussions on using Libmeldy on the NHS • Source: Alamy

Orchard Therapeutics has pledged to work to convince NICE about the value of its gene therapy, Libmeldy (atidarsagene autotemcel), after the health technology assessment (HTA) body recommended against making the treatment available on England’s National Health Service for children with metachromatic leukodystrophy (MLD).

In draft guidance, released for public consultation on 9 June, NICE said it recognized that Libmeldy was an “innovative technology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.